Advertisement

Picture EBD Group BioPharm America 2019 Boston September 650x65px
Document › Details

Horizon Discovery Group plc. (11/17/16). "Press Release: Horizon Discovery Partners with Sophia Genetics on NGS Reference Standards for Oncology Applications". Lausanne & Cambridge.

Organisations Organisation Horizon Discovery Group plc (LSE: HZD)
  Group Horizon Discovery (Group)
  Organisation 2 Sophia Genetics S.A.
  Group Sophia Genetics (Group)
Products Product cell free DNA HDx™ Reference Standards (cfDNA Reference Standards)
  Product 2 Sophia DDM (Data Driven Medicine)
Index term Index term Horizon Discovery–Sophia Genetics: genomic cancer testing, 201611– collab €na integrating HDx Reference Standards w DDM Platform for NGS cancer tests
Persons Person Camblong, Jurgi (Sophia Genetics 201407 CEO + Co-Founder)
  Person 2 Disley, Darrin M. (Mogrify 201902– CEO of Cell Mogrify Ltd before 11 years at Horizon Discovery)
     


§ Partnership combines Horizon’s HDx™ Reference Standards with Sophia Genetics’ artificial intelligence

§ The use of Horizon’s Reference Standards will improve the quality of molecular profiling by SOPHiA™ artificial intelligence in oncology patient samples

§ Users of the Sophia DDM® analytical platform will immediately benefit from the partnership to closely monitor the performance of their genomic tests


Sophia Genetics, the global leader in Data-Driven Medicine, and Horizon Discovery Group plc (LSE: HZD) ("Horizon"), the world-leader in the application of gene editing technologies, today announced they have entered into a new partnership to improve the quality of Next Generation Sequencing (NGS) based genetic testing in oncology patient samples.

Under the terms of the agreement, Horizon’s HDx™ Reference Standards will be combined with Sophia Genetics’ artificial intelligence, providing hospitals and laboratories with more accurate and high quality NGS testing services, assays and genomic data analysis.

In particular, current and future users of the Sophia DDM® analytical platform will be able to assess the quality of their NGS assays, reaching the highest levels of sensitivity and specificity. The use of HDx Reference Standards will help with performance monitoring as well as reproducibility and repeatability of NGS tests.

Jurgi Camblong, Chief Executive Officer and co-founder, Sophia Genetics, commented: “The quality of molecular profiling is a cornerstone of NGS testing and relies on a series of technical steps being performed correctly, from the collection of patient samples and DNA extraction, to creating and analysing genomic data. Sophia Genetics helps hospitals and laboratories to make the most of their NGS testing and we are delighted to combine Horizon’s Reference Standards with our artificial intelligence for Data-Driven Medicine, increasing the number of patients that will benefit from reliable NGS genomic testing results.”

Dr. Darrin M. Disley, Chief Executive Officer, Horizon Discovery Group, commented: “Our new partnership with Sophia Genetics demonstrates the increasingly important role well validated controls have in the provision of molecular assays, especially for complex technologies such as NGS as they become more widely adopted. We look forward to working closely with Sophia Genetics as our Reference Standards become an important component of their workflows.”

Financial terms for the partnership have not been disclosed.


ENDS


Notes to editors:


About NGS Reference Standards

Routine diagnostics call for the highest levels of sensitivity and specificity. The use of Horizon’s HDx Reference Standards provides important insight into assay performance and limitations, monitoring of reproducibility, and insight into the quality of patient samples used as inputs into a workflow. By controlling for these potential sources of variability, the quality of data generated by NGS can be substantially improved.


For further information from Sophia Genetics, please contact:

Alphonse Daudré-Vignier
Weber Shandwick Switzerland
+41 79 127 63 58
ADaudre-Vignier@webershandwick.com


About Sophia Genetics

Sophia Genetics, the global leader in Data-Driven Medicine, brings together expertise in genomics, bioinformatics, machine-learning and data privacy. Based in Switzerland, the company is known for its medical standards and Swiss precision, accuracy and quality management. It offers health professionals performing clinical genomic testing: bioinformatics analysis, quality assurance and genomics data secure banking. Sophia Genetics does not hold personal information, and the data the company holds is anonymised. Developed by the company, SOPHiA™, the world’s most advanced and used artificial intelligence for Data-Driven Medicine, helps laboratories reduce the cost, overcome complexity and fulfil quality constraints related to clinical genomics. For more information, please visit http://www.sophiagenetics.com/ @SophiaGenetics / @JurgiCamblong.



For further information from Horizon Discovery Group plc, please contact:

Zyme Communications (Trade and Regional Media)
Katie Odgaard
Tel: +44 (0)7787 502 947
Email: katie.odgaard@zymecommunications.com


About Horizon Discovery Group plc www.horizondiscovery.com

Horizon Discovery Group plc (LSE: HZD) ("Horizon"), is a world-leading gene editing company that designs and engineers genetically-modified cells and then applies them in research and clinical applications that advance human health.

Horizon’s core capabilities are built around its proprietary translational genomics platform, a highly precise and flexible suite of gene editing tools (rAAV, ZFN and CRISPR) able to alter almost any gene sequence in human or mammalian cell-lines.

Horizon offers over 23,000 catalogue products and related research services, almost all of which are based on the generation and application of cell and animal models that accurately recapitulate the disease-causing genetic anomalies found in diseases like cancer. Horizon’s commercial offering has been adopted by c. 1,600 unique research organisations in over 50 countries as well as in the Company’s own R&D pipeline to support a greater understanding of the genetic drivers of disease and the development of molecular, cell and gene therapies that can be prescribed on a personalised basis.

Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange’s AIM market under the ticker “HZD”.

   
Record changed: 2019-06-22

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for Horizon Discovery (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioPharm America 2019 Boston September 650x65px




» top